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http://dx.doi.org/10.1016/j.pedneo.2The autosomal recessive limb-girdle muscular dystrophy type 2A (LGMD2A) is caused by muta-
tions in the calpain 3 (CAPN3) gene, and it is characterized by selective atrophy and weakness
of proximal limb and girdle muscles. We report a 33-year-old woman with initial presentations
of exercise intolerance and running difficulty at age 15 years. At presentation, waddling gait,
positive Gowers’ sign, and marked muscle atrophy in pelvic and leg muscles were noted. Mus-
cle computed tomography (CT) imaging demonstrated symmetric involvement of the posterior
thigh muscles with relative sparing of vastus lateralis, sartorius, and gracilis. Muscle biopsy
revealed a dystrophic change and many lobulated fibers on NADH-tetrazolium reductase
staining. Genetic analysis of the CAPN3 gene identified a novel homozygous mutation of
c2047_2050 del4, p.Lys683fs mutation, confirming the first LGMD2A patient in Taiwan.
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LGMD Type 2A with CAPN3 mutation 631. Introduction prediction; forced expiratory volume in 1 second: 2.18 L,Limb-girdle muscular dystrophy (LGMD) is a genetically
heterogeneous disease entity, clinically characterized by
progressive involvement and wasting of the shoulder and
pelvic girdle muscles. To date, there are at least 23 dif-
ferent genotypic LGMDs, among which types 1A to 1H are
autosomal dominant inheritance and types 2A to 2Q are
autosomal recessive. LGMD2A is one of the most common
forms of LGMD in European countries, where it affects
about 1 in 100,000 people.1 The clinical features and dis-
ease course are variable; the mean age of disease onset was
17.9 years (range: 2e55 years) and patients became
wheelchair-confined with a mean period of 15.2 years
(range: 4e29 years) from disease onset or at a mean age of
35.2 years. Respiratory and cardiac function were rarely
affected.2,3 Recessive mutations in the CAPN3 gene, which
encodes the calpain-3 protein, are responsible for
LGMD2A.4 Calpain-3 is involved in the regulation of tran-
scription factors controlling survival genes and apoptosis
and in the sarcomere remodeling about degradation and
disassembly of cytoskeletal or myofibrillar proteins.5,6 As
calpain-3 is not a structural protein and disappears very
rapidly in vitro due to autolysis, it is unlikely to be detected
by immunohistochemical staining using muscle biopsy
samples.7
So far, more than 465 different CAPN3 mutations have
been reported to cause LGMD2A worldwide. Herein, we
report the first genetically confirmed LGMD2A patient with
a novel homozygous c2047_2050 del4 CAPN3 mutation in
Taiwan.Figure 1 Muscle image on computed tomography (CT) showed:
(A) asymmetric involvement of shoulder girdles; (B) predominant
hamstring involvement, including SM, ST, and BF; and (C) poste-
rior leg involvement, including S, P, and G. Gr = gracilis;
BF Z biceps femoris; D Z deltoid; G Z gastrocnemius;
ISZ infraspinatus;PZperoneus; SZ soleus; SCZ subscapularis;
SMZ semimembranous; STZ semitendinous.2. Case report
A 33-year-old woman was born of the third pregnancy to
nonconsanguineous parents. Her development milestones
in childhood were normal. She became symptomatic at 15
years of age, presenting with exercise intolerance and
difficulty in running. The disease course was progressive,
and at 18 years of age she had difficulty in climbing stairs
independently. At presentation, she could still walk unai-
ded for over 30 minutes slowly. She could raise her arms
above her head slowly but could not maintain this for long.
Physical and neurological examinations upon the first
visit to our hospital showed decreased muscle power to
grade 2 in proximal lower extremities and grade 3 in
proximal upper extremities according to the Medical
Research Council (MRC) scale. Gowers’ sign was present and
muscle atrophy was markedly visible in pelvic girdle and leg
muscles. There was no facial involvement, but ankle joint
contractures and lordosis were notable. Deep tendon
reflexes were absent in the lower extremities. Laboratory
tests including serum lactate and transaminases levels were
all normal, except for an elevated serum creatine kinase
(CK) level of 914 IU/L (normal range <174 IU/L). Electro-
cardiogram, echocardiogram, and a nerve conduction
velocity study also displayed no abnormal findings. A pul-
monary function test demonstrated moderate restrictive
ventilation (forced vital capacity: 2.21 L, 69.3% of79.3% of prediction).
Muscle computed tomography (CT) exhibited symmetric
involvement of the posterior thigh muscles with relative
sparing of the vastus lateralis, sartorius, and gracilis. At
calf level, the posterior compartment including the soleus,
the medial head of the gastrocnemius, and the fibularis was
much more affected than the tibialis anterior. In the upper
extremities, a mildly asymmetric involvement of the
shoulder girdle, predominantly at the left side, was evident
(Figure 1). A muscle biopsy was then performed on the left
biceps brachii muscle. On hematoxylin and eosin staining,
dystrophic changes including necrotic and regenerating
fibers, marked variation of myofiber size, increased number
of internal nuclei, and moderate endomysial fibrosis were
seen. No eosinophilic infiltration was noted. No inclusions
were found on modified Gomori trichrome staining. Strik-
ingly, numerous atrophic type 1 fibers had disorganized
intermyofibrillar networks showing lobulated appearance
on NADH-tetrazolium reductase (NADH-TR) staining
(Figure 2). Immunohistochemistry analyses for dystrophin,
sarcoglycans, a-dystroglycan, dysferlin, and caveolin-3 all
showed intact staining. Based on the characteristic patho-
logical and image findings, LGMD2A was suspected and
subsequent mutation analysis of the CAPN3 gene identified
a novel homozygous mutation, c.2047_2050 del4
(p.Lys683fs) (Figure 3). Over a 2-year follow-up, the clinical
Figure 2 (A) Hematoxylin-eosin staining showed marked variation of myofiber size, increased number of internal nuclei, mod-
erate endomysial fibrosis, and scattered necrotic and regenerating fibers. (B) On NADH-tetrazolium reductase (NADH-TR), dis-
organized intermyofibrillar networks showing lobulated appearance were seen in many fibers.
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ambulant.
3. Discussion
To our knowledge, this is the first genetically confirmed
LGMD2A patient with CAPN3 mutation in Taiwan. As for
the CAPN3 mutation, missense type was predominant
(60e70%), followed by null type (nonsense, frame-shifting
deletion/insertion, splicing mutations) (30e40%). Most are
clustered in a limited number of exons (exons 1, 4, 5, 8, 10,
11, 21).1,8,9 Our patient carried c.2047_2050 del4
(p.Lys683fs) in exon 18 of the CAPN3 gene, resulting in fra-
meshift mutation and premature termination. Homozygous
patients with null mutations usually show severe clinical
features with rapid progression and earlier onset.1,3,8,10
However, the clinical phenotype of our patient was not as
severe as the case of two null mutations; the onset of the
disease was at the age of 15 years and, at present, she (atFigure 3 Mutation analysis of CAPN3 showed homozygothe age of 33 years) can still walk independently. This
implies that unknown modifiers are also involved in the
pathogenesis, which needs to be further determined.
In terms of clinical manifestations, our patient demon-
strated proximal muscle weakness dominantly. LGMD2A
patients showed typical shoulder and pelvic girdle weak-
ness, which may be unrecognizable from other LGMDs.11
However, neither facial and cardiac involvement nor calf
hypertrophy together with mild to moderate elevation of
CK level can first narrow down the possible diagnosis.12 In
muscle pathology, LGMD2A has been known to show modest
dystrophic features (i.e., degenerating and regenerating
fibers) but chronic myopathic changes (i.e., marked fiber
size variation and lobulated fibers) are evident even at the
early stage.13 However, the considerable proportion of
lobulated fibers shown in our patient has been taken as a
distinguishing histopathological pattern in LGMD2A, which
is rarely seen in other LGMDs.14 A recent study also repor-
ted that two thirds of LGMD2A patients showed lobulatedus c2047_2050del4 mutation in exon 18 (p.Lys683fs).
LGMD Type 2A with CAPN3 mutation 65fibers in the muscle pathology.11 Our report emphasizes the
importance of muscle pathology, which can lead to further
mutation analysis for confirming the final diagnosis.
On muscle CT, patients with LGMD2A have been reported
to have more striking posterior compartment involvement
of thigh (hamstrings) and lower leg (gastrocnemius medial
head and soleus) muscles with relative sparing of the
anterior compartment in the lower limbs.11,15 Our patient
also had similar muscle involvement, predominantly
affecting hamstrings and posterior leg and sparing tibialis
anterior. Accordingly, muscle imaging could be another
tool, which would be of help in the final diagnosis.
In conclusion, this is the first reported Taiwanese
LGMD2A patient with a novel p.Lys683fs mutation. Molec-
ular diagnosis should be considered when characteristic
muscle pathology and imaging are observed. We hope that
our report can further enhance the identification of more
LGMD2A patients and help to elucidate genotypic and
clinical characteristics of these patients in Taiwan.References
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